Sclerosis News and Research

RSS

MRF clinical trial to examine antigen-specific MS therapy

The Myelin Repair Foundation (MRF) announced today that its research might soon lead into a clinical proof-of-concept trial at the Department of Neuroimmunology and Multiple Sclerosis Research (nims), University Hospital Zürich, Switzerland, and the Institute for Neuroimmunology and Clinical Multiple Sclerosis Research (inims) in Hamburg, Germany.

8 Mar 2012

Women with multiple pregnancies may have reduced risk of MS

Women who have multiple pregnancies may have a lower risk of developing multiple sclerosis (MS), according to research published in the March 7, 2012, online issue of Neurology, the medical journal of the American Academy of Neurology.

8 Mar 2012

Researchers document unknown biological mechanism in the blood-brain barrier

Researchers at the University of Copenhagen have documented a previously unknown biological mechanism in the brain's most important line of defence: the blood-brain barrier. Scientists now know that the barrier helps maintain a delicate balance of glutamate, a vital signal compound in the brain.

8 Mar 2012

Concert, Fast Forward partner to advance new approach to treat spasticity and pain in MS

Concert Pharmaceuticals, Inc. and Fast Forward, LLC, the National Multiple Sclerosis Society's subsidiary devoted to bridging the gap between research and drug development, today announced a new collaboration to fund the preclinical advancement of C-21191, a deuterium-modified subtype-selective GABAA modulator developed by Concert with the therapeutic potential of treating spasticity and pain in multiple sclerosis (MS).

5 Mar 2012

AARDA hopes to educate public on autoimmune diseases during March

March is National Autoimmune Diseases Awareness Month, and the American Autoimmune Related Diseases Association (AARDA) is working to educate the public on risk factors, prevalence, and the severe lack of awareness surrounding autoimmune diseases.

3 Mar 2012

Union County Commission honors KF scientist with Women of Excellence Award

Helen Genova, PhD, research scientist at Kessler Foundation, received a Women of Excellence Award in Health Sciences from the Union County Commission on the Status of Women. In the Foundation's Neuropsychology and Neuroscience Laboratory, she investigates the effects of multiple sclerosis (MS) and traumatic brain injury on cognitive function with grant funding.

3 Mar 2012

Parasitic worms could offer new treatment hope for MS patients

Parasitic worms could offer a new treatment hope for patients suffering from the autoimmune disease multiple sclerosis, scientists believe.

1 Mar 2012

SIR to showcase latest minimally invasive treatments at 37th annual meeting

Health, science and medical reporters are invited to register now for the Society of Interventional Radiology's 37th Annual Scientific Meeting March 24 at Moscone Center (North), San Francisco, Calif. The meeting's theme, "IR Evidence," was chosen to focus on the results of care-changing investigations that showcase research into minimally invasive treatments that provide treatment options, advance patient care and improve quality of life.

1 Mar 2012

Researchers refute widely accepted hypothesis about causative step in ALS

In science, refuting a hypothesis can be as significant as proving one, all the more so in research aimed at elucidating how diseases proceed with a view toward preventing, treating, or curing them. Such a discovery can save scientists from spending precious years of effort exploring a dead end. In a study published in the Proceedings of the National Academy of Sciences, Munich-based researchers refute a widely accepted hypothesis about a causative step in neurodegenerative conditions.

1 Mar 2012

KF's TBI research director to speak at Washington conference

Jordan Grafman, PhD, director of Traumatic Brain Injury Research at Kessler Foundation, is an invited speaker at The 2nd Annual Traumatic Brain Injury Conference on March 6, 2012, in Washington, DC. Dr. Grafman will describe the long-term cognitive and social consequences of traumatic brain injury.

1 Mar 2012

New research shows beneficial side effect of anti-allergy parasite

New research is showing a beneficial side effect of parasites for our health. Hygiene Hypothesis: As rates of allergy are reported to have tripled in the UK in the past decade, the scientific finger is pointing to an over-sanitised lifestyle making our immune responses overactive. Now, a team of biologists at the University of Edinburgh, led by Professor Rick Maizels, are investigating how parasitic worms could offer a cure for modern illnesses.

1 Mar 2012

Biogen Idec announces new easier to use injection for multiple sclerosis

The Food and Drug Administration approved the company's Avonex pen, an injection designed to reduce pain and anxiety when patients self-administer the drug. The FDA also approved a new dosing schedule for the drug intended to reduce flu-like symptoms often associated with the drug.

29 Feb 2012

Scientists to speak on cultural issues pertinent to rehabilitation research

Two scientists will represent Kessler Foundation at the 2012 Race, Ethnicity and Disabilities State of the Science Conference on March 1-2 at the Crystal Gateway Marriott in Arlington, Virginia.

29 Feb 2012

Minimally invasive treatments to be showcased at SIR's 37th Annual Scientific Meeting

The Society of Interventional Radiology will feature minimally invasive scientific advances and new discoveries that may change the way dozens of diseases are treated at its 37th Annual Scientific Meeting March 24-29 at San Francisco's Moscone Center.

29 Feb 2012

AAN, ALS Association announce creation of Richard Olney Clinician Scientist Development Award

The American Academy of Neurology Foundation and The ALS Association are announcing the creation of the Richard Olney Clinician Scientist Development Award in ALS, named after Richard K. Olney, MD, a leading neurologist and pioneer in clinical ALS research who died late last month of ALS, also known as amyotrophic lateral sclerosis, or Lou Gehrig's disease.

29 Feb 2012

Cannabinoids may be a target for new strategies in cancer treatment

Cannabis-like substances that are produced by the body have both therapeutic and harmful properties, besides their well-known intoxicating effects, and the body's cannabinoid system may be a target for new strategies in cancer treatment.

29 Feb 2012

Biogen Idec receives FDA approval for two separate dosing innovations to treat MS

Today Biogen Idec announced that the U.S. Food and Drug Administration (FDA) has approved two separate dosing innovations designed to improve the treatment experience for patients receiving once-a-week AVONEX for relapsing forms of multiple sclerosis (MS).

28 Feb 2012

Opexa 2011 net loss increases to $5,968,448

Opexa Therapeutics, Inc., a biotechnology company developing a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the year ended December 31, 2011 and provided an overview of corporate developments during the last year.

27 Feb 2012

Death of myelin sheath producing cells does not trigger MS

Millions of adults suffer from the incurable disease multiple sclerosis (MS). It is relatively certain that MS is an autoimmune disease in which the body's own defense cells attack the myelin in the brain and spinal cord.

27 Feb 2012

KF scientist to speak at William Paterson University, March 1

John DeLuca, PhD, vice president for research at Kessler Foundation, is the featured speaker at the grand opening of the new Science Complex at William Paterson University's College of Science and Health. Dr. DeLuca, a well known expert in cognitive function, will discuss "Neuroimaging, Brain and Behavior: New Opportunities for the Future," on March 1, 2012 12:30 to 1:05 pm in the Science East Lecture Hall.

27 Feb 2012